

physiologically tolerable water-soluble organic polymer characterized in that at 5, 15 and 45 minutes after addition of a quantity of the composition containing 100 mg of drug to 600 ml of 0.1 N hydrochloric acid at 37 °C, from 7 to 25 %, from 45 to 70 % and at least 96 % of drug compound is in solution in said hydrochloric acid.

Amend Claims 2, 4-5, 7, 10-13 and 20 as follows:

2. The composition of claim 22 characterised in that the weight ratios of drug compound to acid and of drug compound to cyclodextrin are no more than 2:1.
4. The composition of claim 22 wherein the cyclodextrin is 2-hydroxypropyl- $\beta$ -cyclodextrin.
5. The composition of claim 22 wherein the acid is selected from the group comprising citric, fumaric, tartaric, maleic, malic, succinic, oxalic, malonic, benzoic, mandelic and ascorbic acid.
7. The composition of claim 22 wherein the polymer is selected from the group comprising
  - alkylcelluloses such as methylcellulose,
  - hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose,
  - hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose,
  - carboxyalkylcelluloses such as carboxymethylcellulose,
  - alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose,
  - carboxyalkylalkylcelluloses such as carboxymethylethylcellulose,
  - carboxyalkylcellulose esters,
  - starches,
  - pectins such as sodium carboxymethylamylopectin,
  - chitin derivatives such as chitosan,

- heparin and heparinoids,
- polysaccharides such as alginic acid, alkali metal and ammonium salts thereof, carrageenans, galactomannans, tragacanth, agar-agar, gum arabic, guar gum and xanthan gum,
- polyacrylic acids and the salts thereof,
- polymethacrylic acids and the salts thereof, methacrylate copolymers,
- polyvinylalcohol,
- polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate,
- polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide, e.g. poloxamers and poloxamines.

10. The composition of claim 22 wherein the drug is a basic compound.

11. A composition according to claim 22 that dissolves rapidly in body fluids, characterized in that it comprises from 50 to 95 % by weight of acid.

12. A composition according to claim 22 that provides sustained release of the drug, characterized in that it comprises a water soluble polymer having an apparent viscosity of more than 1,000 mPa.s when dissolved in a 2% aqueous solution at 20°C.

13. A pharmaceutical dosage form comprising a therapeutically effective amount of a pharmaceutical composition as defined in claim 22.

20. A method of therapy or diagnosis of the human or non-human animal body which comprises administering to said body a therapeutically or diagnostically effective dose of a pharmaceutical composition according to claim 22.